Cancer Biomarkers Conference III
Recent years have seen an accelerating surge in testing for predictive biomarkers to select cancer patients for new molecular targeted therapies for their cancers, often referred to as personalized healthcare or precision medicine, and PD-L1 testing for new immune therapies. This phenomenon has occurred in multiple types of cancer including cancers of the breast, colon, bladder, ovaries, stomach, pancreas, gastrointestinal stromal tumor, prostate, lung, pleura and melanoma. Pathologists select tissues for the biomarker tests, may order the tests, may perform the tests, report the test results and participate in multidisciplinary tumor boards to discuss the tissues, biomarker tests and test results.
Oncologists may order the biomarker tests, treat patients on the basis of the biomarker test results and participate in multidisciplinary tumor boards to discuss the tissues, biomarker tests and test results. Pathologists and oncologists need to know the answers to a host of questions in this rapidly developing field of biomarkers in order to offer the best patient care. These questions include: which cancer patients should have biomarker testing, which biomarker tests should be done for a given patient, what tissue samples are appropriate for a given biomarker test, how should the biomarker tests be performed, how should the biomarker tests be reported and utilized. In addition, there are questions about the options to provide the biomarker testing service in different settings with different resources and specific needs.
The field of biomarkers is growing rapidly due to the discovery of new biomarkers as targets of therapy, approval of new immune therapies and PD-L1 testing and the development of new methodologies for biomarker testing. Recent guidelines for biomarker testing, statements on PD-L1 testing and templates for reporting biomarker test results have been published and more are anticipated in the upcoming months.
The target audience for this activity is: Physicians, nurses, and residents/fellows.
- Distinguish the proper collection, management and submission of pathology specimens for cancer biomarker testing
- State the clinical rationale for patient selection and treatment based on cancer biomarkers
- Define regulations and billing for molecular testing focused on cancer biomarker testing
- Describe the most current biomarkers and testing guidelines for multiple solid cancers and hematologic cancers
For more information and registration, visit: https://events.houstonmethodist.org/cancerbiomarkers
Houston Methodist Research Institute
6670 Bertner Ave., Houston, Texas 77030
Houston Methodist CME